1. Home
  2. KROS vs FAX Comparison

KROS vs FAX Comparison

Compare KROS & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • FAX
  • Stock Information
  • Founded
  • KROS 2015
  • FAX 1986
  • Country
  • KROS United States
  • FAX United States
  • Employees
  • KROS 160
  • FAX N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • FAX Investment Managers
  • Sector
  • KROS Health Care
  • FAX Finance
  • Exchange
  • KROS Nasdaq
  • FAX Nasdaq
  • Market Cap
  • KROS 589.8M
  • FAX 629.1M
  • IPO Year
  • KROS 2020
  • FAX N/A
  • Fundamental
  • Price
  • KROS $14.56
  • FAX $15.00
  • Analyst Decision
  • KROS Buy
  • FAX
  • Analyst Count
  • KROS 11
  • FAX 0
  • Target Price
  • KROS $68.83
  • FAX N/A
  • AVG Volume (30 Days)
  • KROS 2.0M
  • FAX 833.6K
  • Earning Date
  • KROS 02-26-2025
  • FAX 01-01-0001
  • Dividend Yield
  • KROS N/A
  • FAX 12.09%
  • EPS Growth
  • KROS N/A
  • FAX N/A
  • EPS
  • KROS N/A
  • FAX N/A
  • Revenue
  • KROS $651,000.00
  • FAX N/A
  • Revenue This Year
  • KROS $224.66
  • FAX N/A
  • Revenue Next Year
  • KROS N/A
  • FAX N/A
  • P/E Ratio
  • KROS N/A
  • FAX N/A
  • Revenue Growth
  • KROS 8037.50
  • FAX N/A
  • 52 Week Low
  • KROS $13.96
  • FAX $2.33
  • 52 Week High
  • KROS $73.00
  • FAX $2.84
  • Technical
  • Relative Strength Index (RSI)
  • KROS 22.18
  • FAX 38.18
  • Support Level
  • KROS $15.59
  • FAX $14.56
  • Resistance Level
  • KROS $16.49
  • FAX $14.95
  • Average True Range (ATR)
  • KROS 0.80
  • FAX 0.22
  • MACD
  • KROS 0.95
  • FAX 0.01
  • Stochastic Oscillator
  • KROS 16.31
  • FAX 46.32

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities, and others.

Share on Social Networks: